Amarin Corp Plc (AMRN)

[dogn]

Vascepa is first and foremost a proven drug for improving outcomes of patients with CVD, the world’s largest cause of death. Great that PREPARE-IT 2 is testing related benefits for treating other diseases like COVID-19 as even post pandemic it may become a go to add-on treatment for any severe respiratory infection (even seasonal flu, pneumonia, or other serious inflammatory infections). This just expands the market for Amarin’s Vascepa. Since the CVD benefits shown in REDUCE-IT notably grow over time with duration of accumulated drug therapy, shorter term trial might not show as significant a benefit, but informed investors know it remains an important new CVD treatment destined to show large future growth in revenues especially as EU and ROW growth kicks in. So ignore the FUD that PI-2 might underwhelm at upcoming AHA late-breaker… it’s not relevant to Vascepa’s main & substantial CVD market. It’s just more gravy for the mashed potatoes. MM price manipulation will be temporary bump if not nice boost for long term investors. I’m in & trading around dips & rips with now 9500 shares with post DUsaster breakeven ~$6.25, having cut position in half just before Nevada court decision. But small part of overall investments so happy to hold & weather fluctuations as see potential for nice gains with patience. Grateful for this board to keep informed. GLTA